Aralez Pharmaceuticals (TSE:ARZ)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research report issued to clients and investors on Monday.

Aralez Pharmaceuticals (ARZ) opened at C$2.23 on Monday. Aralez Pharmaceuticals has a 1-year low of C$1.20 and a 1-year high of C$6.11. The firm has a market capitalization of $112.54 and a PE ratio of -1.33.

Aralez Pharmaceuticals (TSE:ARZ) last posted its earnings results on Thursday, November 9th. The company reported C($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of C($0.50) by C$0.04. Aralez Pharmaceuticals had a negative return on equity of 146.16% and a negative net margin of 100.42%. The company had revenue of C$30.53 million for the quarter, compared to the consensus estimate of C$29.81 million.

COPYRIGHT VIOLATION WARNING: This report was originally published by Watch List News and is the property of of Watch List News. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at

About Aralez Pharmaceuticals

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Receive News & Ratings for Aralez Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals and related companies with's FREE daily email newsletter.